Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088270
Status:
COMPLETED
Last Update Posted:
2006-02-22
First Post:
2004-07-23
Brief Title:
A Study of OSI-7904L Versus 5-FULV as Treatment in Patients With Biliary Tract Cancer
Sponsor:
OSI Pharmaceuticals
Organization:
OSI Pharmaceuticals
Study Overview
Official Title:
A Randomized Open Label Phase II Study of OSI-7904L Versus 5-FULV as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
Status:
COMPLETED
Status Verified Date:
2004-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multi-center randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FULV in biliary tract cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None